NMN/NR Patent Overview and Generic Timeline

How NMN and NR Raise NAD+ Through Different Enzymatic Steps

Both NMN and NR are precursors to nicotinamide adenine dinucleotide (NAD+), a coenzyme required for over 500 enzymatic reactions in human cells. They enter the NAD+ salvage pathway at different points, and this biochemical distinction has shaped their divergent patent and regulatory stories.

NR (nicotinamide riboside) is phosphorylated by nicotinamide riboside kinases (NRK1 and NRK2) to form NMN, which is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferases (NMNATs) [1]. NMN skips the NRK step entirely and feeds directly into NMNAT-catalyzed conversion. A 2019 review in Cell Metabolism outlined how oral NMN administration in mice increased tissue NAD+ levels within 15 minutes of gavage dosing, suggesting rapid absorption and conversion [2]. In humans, Yoshino et al. demonstrated in a randomized, placebo-controlled trial (N=25) that 250 mg/day oral NMN for 10 weeks improved skeletal muscle insulin sensitivity in postmenopausal women with prediabetes, with significant increases in muscle NAD+ metabolites [3].

NR has its own human data. Martens et al. (2018) showed that 1 to 000 mg/day NR (Niagen) for 6 weeks raised whole-blood NAD+ by approximately 60% in healthy middle-aged and older adults (N=24), with a trend toward reduced aortic stiffness and lower systolic blood pressure [4]. The fact that both compounds reliably raise NAD+ in humans is not disputed. What is disputed is who owns the right to sell them and in what form.

The NR Patent Portfolio: ChromaDex and Dartmouth College

ChromaDex Corporation holds the dominant intellectual property position for NR in the United States. The company's patent estate originates from exclusive licenses with Dartmouth College, Cornell University, and Washington University in St. Louis.

The foundational composition-of-matter patent, U.S. Patent No. 8,197,807 ("Nicotinamide Riboside Compositions"), was issued in 2012 and covers isolated NR in crystalline form for oral administration. This patent expires in 2029, though ChromaDex has built a layered portfolio of continuation patents and method-of-use patents extending coverage into the mid-2030s. U.S. Patent No. 8,383,086 covers methods of increasing NAD+ biosynthesis using NR, with expiration around 2030. U.S. Patent No. 10,596,191 covers specific NR chloride salt formulations (the form used in Niagen) and does not expire until approximately 2033 [5].

ChromaDex has aggressively defended this portfolio. The company filed suit against Elysium Health in 2017 over Elysium's "Basis" product, which contained NR sourced from a non-ChromaDex supplier. That litigation produced multiple rulings and settlements, with ChromaDex largely succeeding in enforcing its supply chain exclusivity [6]. The practical effect: any company seeking to sell NR in the U.S. either licenses from ChromaDex or risks patent infringement litigation.

For generic NR to reach the market, several conditions must align. The '807 patent must expire (2029), and challengers must manage the continuation patents that extend to 2033 or later. No Paragraph IV (Hatch-Waxman) challenge is possible because NR is not an FDA-approved drug with an Orange Book listing. Generic competition will likely emerge through the supplement pathway once core patents lapse, rather than through the ANDA process used for prescription generics.

NMN's Regulatory Crisis: The FDA Supplement Exclusion

NMN's commercial trajectory changed dramatically on November 4, 2022, when FDA responded to two citizen petitions by concluding that NMN could not be marketed as a dietary supplement. The agency's reasoning relied on the drug exclusion clause of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 321(ff)(3)(B)), which bars a substance from the supplement market if it was first authorized for investigation as a new drug before being marketed as a supplement [7].

Metro International Biotech (MIB), co-founded by NAD+ researcher David Sinclair, Ph.D., had filed an IND for MIB-626 (a proprietary NMN formulation) in 2021. FDA determined that this IND predated substantial commercial marketing of NMN as a supplement. The ruling was stark: NMN products already on shelves were technically misbranded.

Industry response was immediate. The Natural Products Association and several NMN manufacturers filed lawsuits challenging FDA's interpretation. In NPA v. FDA (2023), the U.S. District Court for the Southern District of Florida initially sided with FDA, but the case has been appealed. Some manufacturers continued selling NMN, arguing that the compound had been marketed as a supplement before the IND was filed. Amazon removed NMN listings in early 2023, though other retailers continued sales [8].

The situation remains unresolved. If FDA's exclusion stands, NMN's only legal path to the U.S. market is as an approved prescription drug under an NDA filed by Metro International Biotech or another sponsor. If a court overturns the exclusion, NMN returns to the supplement market with no patent barriers (no single entity holds a dominant NMN composition patent comparable to ChromaDex's NR portfolio).

Metro International Biotech and the MIB-626 Drug Development Program

Metro International Biotech is developing MIB-626 as a prescription NAD+ precursor. The company has completed Phase I safety studies and initiated Phase II trials evaluating MIB-626 in conditions including acute kidney injury, COVID-19-related complications, and age-related metabolic dysfunction.

MIB-626 uses a specific crystalline form of beta-nicotinamide mononucleotide, and Metro holds patents on this particular formulation. U.S. Patent No. 11,040,956 covers stable crystalline polymorphs of NMN with defined melting points and X-ray diffraction patterns, providing composition-of-matter protection distinct from NMN as a generic chemical entity [9]. This patent expires approximately in 2040.

If MIB-626 achieves NDA approval, Metro would receive standard regulatory exclusivity: five years of new chemical entity (NCE) exclusivity if NMN qualifies as a new active ingredient not previously approved by FDA, or three years of clinical investigation exclusivity for a new formulation or indication. Five-year NCE exclusivity would block generic ANDA filings until the late 2040s at the earliest, assuming approval occurs around 2028 to 2030.

A critical open question: does NMN qualify as an NCE? The compound exists in the human body as an endogenous metabolite. FDA has not publicly addressed whether endogenous metabolites automatically disqualify from NCE status, but precedent from other endogenous compounds (e.g., melatonin receptor agonists, synthetic testosterone) suggests that a specific pharmaceutical-grade formulation can receive NCE exclusivity even if the active moiety occurs naturally.

Comparing Patent Timelines: NR vs. NMN

The two compounds face fundamentally different intellectual property and regulatory calendars.

For NR, the timeline is relatively predictable. ChromaDex's core composition patent ('807) expires in 2029. The NR chloride salt formulation patent ('191) expires around 2033. Method-of-use patents extend to approximately 2035 to 2037. After core patents expire, generic NR supplement manufacturers can enter the market without ANDA filings because NR is classified as a dietary ingredient, not a drug. The first wave of generic NR products could appear as early as 2029 if manufacturers are willing to challenge the continuation patents, or 2033 to 2034 if they wait for the broadest claims to lapse [10].

For NMN, the timeline is binary and depends on a single regulatory outcome. If FDA's supplement exclusion is overturned (through litigation or legislative action such as proposed bills to amend the FD&C Act), NMN returns to the supplement market immediately with minimal patent barriers. Generic NMN is already manufactured at scale in China and could flood the U.S. market within months. If the exclusion stands and MIB-626 is approved as a drug, generic NMN will not be available until Metro's patents and regulatory exclusivity expire, potentially not until the 2040s.

Dr. Charles Brenner, the University of Iowa biochemist who first characterized NR as a vitamin precursor to NAD+ in 2004, has stated: "The regulatory distinction between NR and NMN is not based on safety or efficacy data. It is based on the sequence of commercial and investigational filings" [11].

International Patent Considerations and Supply Chain Dynamics

Outside the United States, NMN remains widely available as a supplement. Japan, where Yoshino et al. conducted their key 2021 trial [3], classifies NMN as a food ingredient. The Japanese Ministry of Health, Labour and Welfare has not restricted NMN sales, and Japanese manufacturers (including Mitsubishi Corporation and Shinkowa Pharmaceutical) produce pharmaceutical-grade NMN at scale. The European Union classifies NMN as a novel food requiring pre-market authorization under Regulation (EU) 2015/2283, and several applications are under review [12].

China is the world's largest NMN producer. Enzymatic biosynthesis methods developed by Chinese manufacturers have driven bulk NMN powder prices below $100 per kilogram (wholesale), compared to $300 to $500 per kilogram for NR. Multiple Chinese companies hold process patents on NMN production methods, but these do not confer composition-of-matter exclusivity in the U.S. [13].

For NR, ChromaDex's international patent portfolio is narrower than its U.S. position. Some international markets have seen generic NR products from manufacturers who operate outside ChromaDex's patent jurisdiction. This creates a patchwork of availability: branded Niagen (ChromaDex-licensed) dominates in the U.S., Canada, and parts of Europe, while unlicensed NR and NMN products circulate in Asia and through direct-to-consumer international shipping.

Purity, Stability, and Why Patent Status Affects Product Quality

Patent monopolies have a side effect: they create economic incentives for quality control. ChromaDex's Niagen undergoes third-party testing for NR content, heavy metals, and microbial contamination, and the company publishes certificates of analysis. Products manufactured under patent protection typically maintain tighter specifications because the patent holder's brand reputation depends on consistent quality [14].

The NMN market, by contrast, has operated in a regulatory gray zone since 2022. Products sold by U.S. retailers may originate from Chinese bulk manufacturers with variable quality control. A 2023 analysis by ConsumerLab found that 3 of 12 tested NMN supplements contained less than 80% of their labeled NMN content, and one product contained detectable levels of nicotinamide (a degradation product) above 5% [15]. NMN is hygroscopic and degrades in the presence of moisture and heat, making storage and encapsulation conditions critical.

This quality variance is clinically relevant. Yoshino et al. used pharmaceutical-grade NMN manufactured under GMP conditions [3]. Consumers purchasing unregulated NMN products cannot assume bioequivalence with the material used in clinical trials. If MIB-626 achieves NDA approval, it would become the first NMN product with FDA-verified manufacturing standards, potency, and bioavailability data.

What Clinicians Should Tell Patients Right Now

Patients asking about NMN and NR deserve a direct answer about what is legally available and what the evidence supports.

NR (as Niagen/TruNiagen) is the only NAD+ precursor with an established regulatory pathway, a strong patent position, published human safety data from multiple trials, and FDA-accepted new dietary ingredient (NDI) notification status. Martens et al. demonstrated safety and tolerability at 1 to 000 mg/day for 6 weeks in older adults [4], and a longer 12-week trial by Elhassan et al. (2019) confirmed sustained NAD+ elevation and favorable safety profiles in the same population [16]. NR's side effect profile in published trials is limited to mild GI symptoms (nausea, bloating) at doses above 1 to 000 mg/day.

NMN has promising but limited human efficacy data. The Yoshino trial (N=25) is the most cited, but the sample size is small, the duration was only 10 weeks, and the primary endpoint (muscle insulin sensitivity measured by hyperinsulinemic-euglycemic clamp) is a surrogate, not a clinical outcome [3]. Larger trials are needed. Patients who currently use NMN purchased from non-U.S. sources or remaining U.S. inventory should be counseled on the quality control risks described above.

The Endocrine Society has not issued formal guidelines on NAD+ precursor supplementation for any indication. The American Academy of Anti-Aging Medicine (A4M) includes NAD+ optimization in its fellowship curriculum but has not published consensus dosing recommendations [17]. Prescribers considering NAD+ precursor therapy should document the clinical rationale (e.g., insulin resistance, age-related NAD+ decline) and monitor patients with periodic metabolic panels including fasting glucose, HbA1c, and lipid profiles.

Baseline NAD+ measurement is not available through standard clinical laboratories. Research-grade whole-blood NAD+ assays exist (used by Martens et al. to document the 60% increase with NR [4]), but these are performed by specialty labs and cost $150 to $300 per sample. Until point-of-care NAD+ testing becomes available, clinicians must rely on downstream metabolic markers to assess response.